Cromos Pharma, where the patients are

Archives

Choose a date range

From To

Choose one or more categories

Categories:



 


Evotec inks agreements with Debiopharm Group, Convergence

Monday, April 7, 2014 12:37 PM

Evotec, a drug discovery alliance and development partnership company, has formed a research collaboration and licensing deal with Debiopharm Group, a Swiss-based global biopharmaceutical group, to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemias with defined genetic alterations.

More... »

CRF Health eCOA webinar series

WuXi PharmaTech invests in TruTag security platform for drug safety

Monday, April 7, 2014 12:36 PM

CRO WuXi PharmaTech, with operations in China and the U.S., and TruTag Technologies, developer of an edible, covert security platform to address the global product counterfeiting challenge, have announced that WuXi Corporate Venture Fund has made an investment in TruTag.

More... »


Seoul National University Hospital, OmniComm Systems ink agreement

Monday, April 7, 2014 12:35 PM

OmniComm Systems, a global provider of clinical data management solutions for clinical trials, signed a five-year agreement with Seoul National University Hospital (SNUH) Clinical Trials Center, an academic medical center in the Republic of Korea, to use OmniComm Systems' TrialOne technology for automation within its phase I clinical pharmacology studies.

More... »

Merck, Ferring, WHO work to prevent post-partum hemorrhage

Monday, April 7, 2014 12:33 PM

Merck and Ferring Pharmaceuticals are collaborating with the World Health Organization (WHO) to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding (post-partum hemorrhage) in women after childbirth, which is designed to be stable at room temperature, even in hot and tropical climates (ICH climatic zone IV).

More... »

Sun Pharma to acquire Ranbaxy for $4 billion

Monday, April 7, 2014 12:31 PM

India-based Sun Pharma, an international, integrated, specialty pharmaceutical company, will acquire Ranbaxy Laboratories, an integrated, research-based, international pharmaceutical company, in an all-stock transaction.

More... »

The Pulse on Global Trials By Matthew Howes

Monday, April 7, 2014 09:00 AM

Are your recruitment and retention goals for clinical trials in developing markets realistic?

More... »

Proposed health IT strategy aims to promote innovation, protect patients, avoid duplication

Friday, April 4, 2014 12:05 PM

HHS has released a draft report that includes a proposed strategy and recommendations for a health information technology (health IT) framework, which promotes product innovation while maintaining appropriate patient protections and avoiding regulatory duplication. The congressionally mandated report was developed in consultation with health IT experts and consumer representatives and proposes to clarify oversight of health IT products based on a product’s function and the potential risk to patients who use it.

More... »

Rosetta Genomics, Marina Biotech ink alliance for rare diseases

Friday, April 4, 2014 12:02 PM

Rosetta Genomics, a developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, a nucleic acid-based drug discovery and development company focused on rare diseases, have established a strategic alliance to identify and develop microRNA-based products designed to diagnose and treat various neuromuscular diseases and dystrophies.

More... »

Actavis launches Asia Pacific regional headquarters in Singapore

Friday, April 4, 2014 12:01 PM

Actavis, a global specialty pharmaceutical company, has opened its new regional office in Singapore, which will serve as the headquarters for the company's Asia Pacific and Africa (APACA) region.

More... »

IntegraGen, Pfizer collaborate

Friday, April 4, 2014 12:00 PM

IntegraGen, a developer and marker of molecular diagnostic testing in oncology and autism, has entered into an agreement with Pfizer that provides Pfizer access to evaluate the company’s proprietary molecular signature for hepatocellular carcinoma. The 56-gene molecular signature covered by the agreement is intended to predict the clinical prognosis of patients with hepatocellular carcinoma and subcategorize patients into six separate classifications based on the molecular characteristics of their liver tumors.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs